Press "Enter" to skip to content

Pfizer/BioNTech to apply to FDA for third-dose Covid-19 vaccine authorization – Health News

In a statement made to the Associated Press, it was noted that the company will apply to the FDA for approval of a third dose of vaccine in order to increase immunity to the epidemic and potentially stop the spread of Covid-19 variants.

In the statement, it was stated that the current vaccine was updated against the Delta variant that emerged in India, and it was stated that the third dose of Covid-19 vaccine, which will be made within 12 months after the second dose, will have a strong effect on preventing new variants of the virus.

The Covid-19 vaccine, named BNT162b2, developed by Pfizer and BioNTech, was given “emergency use approval” by the FDA on December 11, 2020 to combat the pandemic.

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *